Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363181 · ClinicalTrials.gov registry record
Side Effects of Antipsychotic Medications
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 76
- Enrollment target
NCT00363181: Completed study, sponsored by Stanford University.
NCT00363181 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363181 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363181
The ClinicalTrials.gov registry entry for NCT00363181 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00363181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363181 about?
NCT00363181 is a clinical study titled "Side Effects of Antipsychotic Medications". Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine d...
What is the current status of trial NCT00363181?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2006-04. Estimated completion is 2011-12.
Who is sponsoring clinical trial NCT00363181?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.